Profile: Isoray, Inc. utilizes its patented radioisotope technology,to create a major therapeutic medical isotope and medical device company with a goal of providing improved patient outcomes in the treatment of prostate cancer and other solid cancer tumors. Our product includes isoray medicalTM , isoray 131Cs brachytherapy seed for the treatment of prostate cancer and cesium-131 brachytheraphy seeds which decreases radiation exposure to the patient and reduces the severity and duration of side effects, while treating cancer cells as effectively. Cesium-131 also enables meaningful penetration in other solid tumor applications such as breast, lung, liver, brain and pancreatic cancer.

FDA Registration Number: 3005520039